Table 10.
Ligand | Origin | Selectivity | Cells | Effects | Ref. | Potency |
---|---|---|---|---|---|---|
Quin-C1 | Combinatorial library | FPR2 | Neutrophils; FPR2-expressing cells | chemotaxis; β-glucuronidase secretion | [142] | pEC50 = 5.72 |
FPR2/RBL | Ca2+ mobilization; ERKs activation | [142] | ||||
Mouse model | anti-inflammatory; reduction of the expression of TNF-α, IL-1β, keratinocyte-derived chemokine, TGF-β1 and CXCL10 | [143] | ||||
Pyrazolone 24/43 | Combinatorial library | FPR2 | FPR2-transfected cells | anti-inflammatory; Ca2+ mobilization | [144] | pIC50 = 7.36 |
Aryl carboxylic acid hydrazide derivatives | Chemolibrary of drug-like molecules | FPR2 | Monocytes; Macrophages; Phagocytes | TNFα production; Ca2+ mobilization; reactive oxygen species production; chemotaxis | [145] | EC50 = 2 μM |
Pyridazin-derivatives | Ligand-based drug design approach | FPR1/FPR2 | Neutrophils | Ca2+ mobilization; chemotaxis | [146] | EC50 = 13.1 μM |
AG-26, AG-09/4-AG09/8 | Chemolibrary of drug-like molecules | FPR2 | FPR2-transfected RBL-2H3 | Ca2+ mobilization | [84] | EC50 = 0.5 μM, 0.3–12.6 μM |
PD168368; PD176252; A-716223 | Screening of known GPCR ligands | FPR1/FPR2 | FPRs-transfected HL-60; Neutrophils | Ca2+ mobilization; reactive oxygen species production | [147] | EC50 = 0.5 μM, 0.9 μM, 18.3 μM |
pEC50, negative logarithm of the EC50; pIC50, negative logarithm of the IC50.